Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2− advanced breast cancer: Final results of the randomized phase III MONARCH plus trial

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2− advanced breast cancer: Final results of the randomized phase III MONARCH plus trial

Abstract. Background:. In the interim analysis of MONARCH plus, adding abemaciclib to endocrine therapy (ET) improved progression-free survival (PFS) and objective response rate (ORR) in predominantly Chinese postmenopausal women with HR+/HER2− advanced breast cancer (ABC). This study presents the...

Full description

Saved in:
Bibliographic Details
Main Authors: Xichun Hu, Qingyuan Zhang, Tao Sun, Yongmei Yin, Huiping Li, Min Yan, Zhongsheng Tong, Man Li, Yue’e Teng, Christina Pimentel Oppermann, Govind Babu Kanakasetty, MA Coccia Portugal, Liu Yang, Wanli Zhang, Zefei Jiang, Sihan Zhou, Xiuyuan Hao
Format: Article
Language:English
Published: Wolters Kluwer 2025-06-01
Series:Chinese Medical Journal
Online Access:http://journals.lww.com/10.1097/CM9.0000000000003151
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://journals.lww.com/10.1097/CM9.0000000000003151

Similar Items